Topical Alprostadil Treatment of Female Sexual Arousal Disorder

Annals of Pharmacotherapy - Tập 40 Số 7-8 - Trang 1369-1376 - 2006
Luba A. Kielbasa1,2, Karen L. Daniel3
1College of Pharmacy, Nova Southeastern University, Ft. Lauderdale, FL
2College of Pharmacy, Nova Southeastern University, Ft. Lauderdale, FL; now, Cardiovascular Pharmacogenomics Fellow, Center for Pharmacogenomics, College of Pharmacy, University of Florida, Gainesville, FL
3Pharmacy Services, College of Pharmacy, Nova Southeastern University

Tóm tắt

Objective: TO review the pharmacology, pharmacokinetics, efficacy, and safety of topical alprostadil in the treatment of female sexual arousal disorder (FSAD). Data Sources: A literature search was conducted using MEDLINE (1966–May 2006), EMBASE, and International Pharmaceutical Abstracts with the search terms alprostadil, female, and sexual dysfunction/drug therapy. Study Selection and Data Extraction: All published and unpublished clinical trials and abstracts involving the efficacy and safety of topical alprostadil use in women were reviewed. Data on file with the manufacturer were also included. Data Synthesis: Topical alprostadil is a vasodilatory agent under development for the treatment of FSAD. In-clinic application of alprostadil increases genital vasocongestion, vaginal erythema, transudates, and some patient-assessed indices of sexual arousal; however, these effects have not been consistently superior to placebo. Three of 4 trials investigating at-home use of topical alprostadil have demonstrated improvements in achievement of satisfactory levels of sexual arousal and successful sexual encounters in patients with FSAD. Adverse events appear to be mild and localized and consist of burning and itching at the application site. Conclusions: Two formulations of topical alprostadil are in Phase II clinical trials for the treatment of FSAD. Initial results of clinical trials have demonstrated some beneficial effects on arousal success rates and other subjective measures of sexual arousal; however, these results have been inconsistent and not reproducible in all trials. The results of ongoing clinical studies are needed to further define the role of topical alprostadil in the treatment of FSAD.

Từ khóa


Tài liệu tham khảo

10.1001/jama.281.6.537

10.1093/fampra/15.6.519

10.1080/00926239308404902

10.1093/oxfordjournals.pubmed.a024665

10.1016/S0090-4295(99)00230-7

Masters EH, 1966, Human sexual response

Kaplan HS, 1974, The new sex therapy

10.1016/S0022-5347(05)67828-7

10.1159/000020247

10.1016/j.sram.2004.07.002

American Psychiatric Association., 2000, DSM-IV-TR: Diagnostic and statistical manual of mental disorders, 4

10.1517/13543784.10.1.85

10.1016/S0015-0282(02)02966-7

10.1080/713846798

10.1023/A:1019896226072

10.1080/009262300278597

FSFI. www.fsfiquestionnaire.com (accessed 2005 Oct 14).

10.1080/00926230290001448

FDA guidance document, guidance for industry. Female sexual dysfunction: clinical development of drug products for treatment. www.fda.gov/cder/guidance/3312.htm (accessed 2005 Oct 14).

10.1080/00926230590909989

10.1007/s00345-002-0273-4

10.2165/00002512-200421100-00004

10.1089/152460902317586001

10.1080/713846815

Caruso S, 2001, BJOG, 108, 623

Alprostadil (NexMed)., 1999, Drugs R D, 2, 413, 10.2165/00126839-199902060-00011

Product information., 2002, Befar (alprostadil–prostaglandin El cream)

2006, Micromedex healthcare series

McEvoy GK, 2005, AHFS drug information

10.1080/713846804

Gittelman M, 2002, Presented at: 97th Annual Meeting of the American Urological Association

10.1080/00926230390224710

Kuffel S, 2004, Presented at: Annual Meeting of the International Society for the Study of Women's Sexual Health

Gittelman M, 2003, Presented at: Annual Meeting of the International Society for the Study of Women's Sexual Health

10.1016/j.fertnstert.2005.07.327

Gittelman MC, 2005, Presented at: 8th Congress of the European Society for Sexual Medicine

Gittelman MC, 2005, Presented at: 8th Congress of the European Society for Sexual Medicine

VIVUS press release. http://ir.vivus.com/phoenix.zhtml?c=79161&p=irol-newsArticle&ID=793669&highlight= (accessed 2006 May 18).

Thông tin
Thông tin xuất bản

Annals of Pharmacotherapy

Tập 40 Số 7-8

1369-1376

Thông tin tác giả